China Pharma Holdings, Inc. — FY2022 Form 10-K
Reporting period: Year ended December 31, 2022; comparisons are to FY2021. The company develops, manufactures and markets pharmaceuticals and healthcare products in China. Its operations and manufacturing are concentrated in Hainan Province.
Financial performance and condition
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $8.10 million | $9.64 million |
| Cost of revenue | $8.60 million | $9.29 million |
| Gross profit (loss) | $(0.49) million; gross margin (6.1%) | $0.35 million; gross margin 3.6% |
| Operating loss | $(3.55) million | $(2.86) million |
| Net loss | $(3.97) million | $(3.40) million |
| Loss per share, basic and diluted | $(0.76) | $(0.74) |
| Cash used in operating activities | $(0.41) million | $(0.25) million |
| Cash and cash equivalents at year-end | $2.03 million | $4.86 million |
- Revenue declined 16%, which management attributed to exchange-rate movements, COVID-19-related restrictions and disruption, and reduced sales of certain products. CNS/cerebral-cardiovascular revenue fell 37% to $1.70 million; anti-infection and respiratory revenue fell 5% to $4.94 million. Digestive-disease revenue rose to $0.40 million.
- Management cited lower selling prices for major products and higher raw-material purchase prices as reasons for the shift from gross profit to gross loss. Selling expenses fell to $1.07 million; general and administrative expenses rose to $1.89 million; research and development expense was $0.19 million.
- Year-end current assets were $5.96 million and current liabilities $12.74 million, including a $3.80 million convertible note classified as current. Total liabilities were $13.49 million; stockholders’ equity was $4.29 million. Net accounts receivable was $0.42 million and inventory $2.95 million.
- Current lines of credit were $2.44 million, due in 2023. The company also reported $2.48 million of current borrowings from related parties. A $10 million RMB Bank of China facility, secured by the production facility and equipment and personally guaranteed by the CEO, was due September 28, 2023.
- Cash declined by $2.83 million during the year. Investing activities used $0.40 million, principally for equipment; financing activities used $1.77 million, largely reflecting debt repayments. The company said its $2.03 million cash balance was considered indefinitely reinvested in its Chinese subsidiary and not expected to be available to the parent or shareholders.
Material changes and notable items
- The company’s net loss widened by about $0.57 million year over year, and gross results deteriorated from profit to loss as revenue declined and cost of revenue exceeded sales.
- Shares outstanding increased during 2022 through note conversions and stock issued for intangible assets and services. The company issued 1,552,229 shares for a technology transfer valued at $1.71 million. A 1-for-10 reverse stock split took effect March 6, 2023; share data in the financial statements is retroactively adjusted for the split.
- The convertible note had $3.80 million principal at December 31, 2022 and matured February 17, 2023. As of the filing, the company said it was negotiating an extension and no event of default had occurred. The investor made additional redemptions converted into shares in January and March 2023; the filing text does not provide a clear remaining balance after those transactions.
- Accounts receivable aging warrants attention: the filing reports 97.44% of receivables were over 720 days old at December 31, 2022, while the net receivable balance was $0.42 million after a $16.74 million allowance. Three customers represented 52.9%, 11.4% and 10.4% of accounts receivable.
- The company acquired rights relating to an ophthalmic oxygen-enriched atomization device in exchange for shares; additional service fees may be payable if the related invention patent is authorized and the product launches.
Outlook, risks and contingencies
- Going concern: The independent auditor expressed substantial doubt about the company’s ability to continue as a going concern, citing recurring operating losses, net current liabilities and accumulated deficit. Management plans to promote advance payments, strengthen receivables collection, pursue healthcare-product launches and seek loans using fixed assets as collateral. The auditor noted these plans do not eliminate the uncertainty; the financial statements include no adjustments for a possible outcome.
- Business outlook: No quantified revenue or earnings guidance is provided. Management describes generic-drug consistency evaluations, healthcare products, and potential digital-health and contract-manufacturing opportunities as strategic priorities. It cautions that centralized procurement and insurance cost controls can lower drug prices and profitability. The filing describes one product’s consistency-evaluation application as undergoing technical review and awaiting on-site verification.
- Regulatory and operating risks: Production may be suspended if facilities fail inspections under China’s revised drug law. The business is exposed to product-approval and consistency-evaluation requirements, price competition, distributor dependence, supply and pandemic disruptions, and changes in Chinese policy, currency controls and regulation.
- Financing and dilution: The convertible note permits conversion or redemption at prices tied to market trading prices, and additional equity financing could dilute shareholders. Management says additional financing may be needed; availability and terms are uncertain. The company reported no off-balance-sheet arrangements.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to a material weakness involving insufficient personnel knowledgeable in U.S. GAAP. Remediation efforts include training and process review. The auditor issued an unqualified opinion on the financial statements, but did not provide an opinion on internal-control effectiveness.
- Other matters: The company reported no legal proceedings believed to have a material adverse effect. It has limited insurance, including no product-liability, business-interruption or directors-and-officers insurance. It does not anticipate paying cash dividends.
Important facts for investors to verify
- Whether the matured convertible note was extended, repaid or otherwise resolved, and its remaining balance and conversion-related dilution after the reported 2023 redemptions.
- Current cash availability, debt maturities and access to financing, including whether management’s going-concern plans have been implemented.
- Recoverability and collection status of the heavily aged receivables, including balances due from the three largest receivable customers.
- Progress and costs of product consistency evaluations, regulatory approvals and any impact on eligibility for centralized procurement.
- Remediation of the material weakness in U.S. GAAP accounting and financial-reporting controls.
- Whether reported share counts and ownership figures reflect the reverse split and subsequent note conversions consistently across filing disclosures.